Filing Flows › Utah Medical Products (UTMD) › Q2 2026 › vs Q2 2025
Utah Medical Products (UTMD) Q2 2026 vs Q2 2025 (year over year)
Utah Medical Products's revenue fell $1.4M (-14%) from $10.0M in Q2 2025 to $8.5M in Q2 2026. Gross margin 55.8% against 56.2% (-0.4 pts).
Utah Medical Products, Q2 2026: revenue $8.5M (-14% year over year), operating margin 31.1%, net earnings $2.7M, operating cash flow $1.4M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 55.8% | 56.2% | -0.4 pts |
| Operating margin | 31.1% | 32.1% | -1.1 pts |
| Net margin | 31.5% | 30.6% | +0.9 pts |
| Free cash flow margin | 14.6% | 28.4% | -13.7 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.5M | $10.0M | −$1.4M | -14% |
| Gross profit | $4.8M | $5.6M | −$837K | -15% |
| Cost of revenue | $3.8M | $4.4M | −$587K | -13% |
| Other income, net | $637K | $640K | −$3K | -0.5% |
| Operating profit | $2.6M | $3.2M | −$547K | -17% |
| Operating expenses | $2.1M | $2.4M | −$290K | -12% |
| Pre-tax earnings | $3.3M | $3.8M | −$550K | -14% |
| Research & development | $154K | $135K | $19K | +14% |
| SG&A | $2.0M | $2.3M | −$309K | -14% |
| Net earnings | $2.7M | $3.0M | −$362K | -12% |
| Income tax | $600K | $788K | −$188K | -24% |
| Depreciation & amortization | $226K | $744K | −$518K | -70% |
| Share-based compensation | $72K | $86K | −$14K | -16% |
| Working capital & other | $1.6M | $1.0M | $596K | +59% |
| Operating cash flow | $1.4M | $2.9M | −$1.5M | -52% |
| Free cash flow (OCF − capex) | $1.2M | $2.8M | −$1.6M | -56% |
| Capital expenditures | $134K | $51K | $83K | +163% |
Questions
How much did Utah Medical Products's revenue grow year over year in Q2 2026?
Utah Medical Products's revenue fell $1.4M (-14%) from $10.0M in Q2 2025 to $8.5M in Q2 2026. Gross margin 55.8% against 56.2% (-0.4 pts).